NGM Biopharmaceuticals Inc (OQ:NGM)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 333 Oyster Point Blvd
SOUTH SAN FRANCISCO CA 94080-1978
Tel: N/A
Website: https://www.ngmbio.com
IR: See website
<
Key People
William J. Rieflin
Executive Chairman of the Board of Directors
Aetna Wun Trombley
President, Chief Operating Officer
David J. Woodhouse
Chief Executive Officer, Acting Chief Financial Officer, Director
Jin-Long Chen
Founder, Chief Scientific Officer, Director
Valerie L. Pierce
Senior Vice President, Chief Compliance Officer, General Counsel
Alex M. DePaoli
Vice President - Clinical Research
Wenyan Shen
Vice President - Biologics
Hui Tian
Vice President - Research
Marc Learned
Executive Director, Research Operations
Business Overview
NGM Biopharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing novel therapeutics for the cardio-metabolic, liver, oncologic and ophthalmic diseases. The Company's product candidates include NGM282, NGM313, NGM386, NGM395, NGM120, NGM217 and NGM621. NGM282 is an engineered variant of the human hormone known as FGF19, which the Company is developing for the treatment of non-alcoholic steatohepatitis (NASH). NGM313 is an agonistic antibody selectively activating fibroblast growth factor receptor 1c-beta-klotho and has the potential as an insulin sensitizer for the treatment of type two diabetes and NASH. NGM386 and NGM395 are engineered variants of the human hormone known as GDF15, which is developed for the treatment of obesity. NGM120 is an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, that is designed to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome, and cancer.
Financial Overview
For the nine months ended 30 September 2019, NGM Biopharmaceuticals Inc revenues increased 18% to $72.5M. Net loss increased 83% to $26.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancin increase of 31% to $82.1M (expense), General and administrative - Balanci increase of 51% to $13.2M (expense).
Employees: 164 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $806.55M as of Sep 30, 2019
Annual revenue (TTM): $119.58M as of Sep 30, 2019
EBITDA (TTM): -$11.26M as of Sep 30, 2019
Net annual income (TTM): -$12.69M as of Sep 30, 2019
Free cash flow (TTM): -$22.10M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 66,155,613 as of Sep 30, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization